Results 31 to 40 of about 28,722 (228)

RNA Combined with Nanoformulation to Advance Therapeutic Technologies

Pharmaceuticals, 2023
Nucleic acid-based therapies have the potential to address numerous diseases that pose significant challenges to more traditional methods. RNA-based therapies have emerged as a promising avenue, utilizing nanoformulation treatments to target a range of ...
Eduarda Santos Lima, Déborah dos Santos, Atena Liriel Souza, Maria Eduarda Macedo, Mariana Evangelista Bandeira, Sérgio Santos Silva Junior, Bianca Sampaio Dotto Fiuza, Vinicius Pinto Costa Rocha, Larissa Moraes dos Santos Fonseca, Danielle Devequi Gomes Nunes, Katharine Valéria Saraiva Hodel, Bruna Aparecida Souza Machado   +11 more
doaj   +1 more source

An Update on Self-Amplifying mRNA Vaccine Development

Vaccines, 2021
This review will explore the four major pillars required for design and development of an saRNA vaccine: Antigen design, vector design, non-viral delivery systems, and manufacturing (both saRNA and lipid nanoparticles (LNP)).
Anna K. Blakney, Shell Ip, Andrew J. Geall   +2 more
doaj   +1 more source

Conjugation of Mannans to Enhance the Potency of Liposome Nanoparticles for the Delivery of RNA Vaccines

Pharmaceutics, 2021
Recent approval of mRNA vaccines to combat COVID-19 have highlighted the potential of this platform. Lipid nanoparticles (LNP) is the delivery vehicle of choice for mRNA as they prevent its enzymatic degradation by encapsulation.
Roshan Goswami, Derek T. O’Hagan, Roberto Adamo, Barbara C. Baudner   +3 more
doaj   +1 more source

Nonviral delivery of self-amplifying RNA vaccines [PDF]

Proceedings of the National Academy of Sciences, 2012
Despite more than two decades of research and development on nucleic acid vaccines, there is still no commercial product for human use. Taking advantage of the recent innovations in systemic delivery of short interfering RNA (siRNA) using lipid nanoparticles (LNPs), we developed a self-amplifying RNA vaccine.
Andrew J, Geall, Ayush, Verma, Gillis R, Otten, Christine A, Shaw, Armin, Hekele, Kaustuv, Banerjee, Yen, Cu, Clayton W, Beard, Luis A, Brito, Thomas, Krucker, Derek T, O'Hagan, Manmohan, Singh, Peter W, Mason, Nicholas M, Valiante, Philip R, Dormitzer, Susan W, Barnett, Rino, Rappuoli, Jeffrey B, Ulmer, Christian W, Mandl   +18 more
openaire   +2 more sources

The next generation of RNA vaccines: self-amplifying RNA [PDF]

The Biochemist, 2021
The global COVID-19 pandemic has brought tremendous momentum to the field of messenger RNA (mRNA) vaccines. The advantages of this vaccine platform, such as rapid development and high efficacy, resulted in mRNA vaccines being the first approved vaccines against COVID-19.
openaire   +1 more source

A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2

Vaccines, 2023
mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have played a key role in reducing morbidity and mortality from coronavirus disease 2019 (COVID-19).
Takenao Koseki, Mayumi Teramachi, Minako Koga, Minoru S. H. Ko, Tomokazu Amano, Hong Yu, Misa Amano, Erica Leyder, Maria Badiola, Priyanka Ray, Jiyoung Kim, Akihiro C. Ko, Achouak Achour, Nan-ping Weng, Takumi Imai, Hisako Yoshida, Satsuki Taniuchi, Ayumi Shintani, Hidetsugu Fujigaki, Masashi Kondo, Yohei Doi   +20 more
doaj   +1 more source

Design-of-experiments in vitro transcription yield optimization of self-amplifying RNA [PDF]

F1000Research, 2021
Background: Self-amplifying RNA (saRNA) vaccines are able to induce a higher antigen-specific immune response with a more cost-effective and rapid production process compared to plasmid DNA vaccines. saRNAs are synthesized through in vitro transcription (IVT); however ...
Karnyart Samnuan, Anna K. Blakney, Paul F. McKay, Robin J. Shattock   +3 more
openaire   +1 more source

Improvement in the potency of a N¹-methylpseudouridine-modified self-amplifying RNA through mutations in the RNA-dependent RNA polymerase. [PDF]

J Biol Chem
ABSTRACT RNA vaccines are sensed as non-self molecules by the innate immune system, and balancing control of the immune activation and vaccine safety and efficacy has remained a challenge, especially for self-amplifying RNAs (saRNAs).
Quintana V, Caillava J, Byk LA, Mondotte JA, Battini L, Tarte P, Samsa MM, Filomatori CV, Alvarez DE.   +8 more
europepmc   +3 more sources

Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies

Frontiers in Immunology, 2022
We assessed if immune responses are enhanced in CD-1 mice by heterologous vaccination with two different nucleic acid-based COVID-19 vaccines: a next-generation human adenovirus serotype 5 (hAd5)-vectored dual-antigen spike (S) and nucleocapsid (N ...
Adrian Rice, Mohit Verma, Emily Voigt, Peter Battisti, Sam Beaver, Sierra Reed, Kyle Dinkins, Shivani Mody, Lise Zakin, Shiho Tanaka, Brett Morimoto, C. Anders Olson, Elizabeth Gabitzsch, Jeffrey T. Safrit, Patricia Spilman, Corey Casper, Corey Casper, Patrick Soon-Shiong   +17 more
doaj   +1 more source

Self-Amplifying RNA Viruses as RNA Vaccines

International Journal of Molecular Sciences, 2020
Single-stranded RNA viruses such as alphaviruses, flaviviruses, measles viruses and rhabdoviruses are characterized by their capacity of highly efficient self-amplification of RNA in host cells, which make them attractive vehicles for vaccine development.
openaire   +2 more sources